Core Insights - BeiGene (ONC.US) shares rose over 3% to $332.26 following a strong quarterly earnings report [1] Financial Performance - In Q3, BeiGene's revenue surpassed 10 billion yuan, reaching 10.077 billion yuan, a year-on-year increase of 41.1% [1] - Product revenue continued to grow rapidly, achieving 9.954 billion yuan, up 40.6% year-on-year [1] - For the first three quarters of 2025, BeiGene's revenue reached 27.595 billion yuan, a 44.2% increase compared to the previous year [1] - The company's product revenue for the same period was 27.314 billion yuan, reflecting a 43.9% year-on-year growth [1] - Net profit attributable to shareholders was 1.139 billion yuan, driven by significant product revenue growth and improved cost management [1] Guidance and Adjustments - Due to strong Q3 performance, BeiGene raised its full-year revenue guidance for 2025, now expecting revenue between 36.2 billion and 38.1 billion yuan, up from a previous range of 35.8 billion to 38.1 billion yuan [1] - The revenue growth adjustment is primarily attributed to the leading position of Brukinsa (Zebutinib) in the U.S. market and its ongoing expansion in Europe and other key global markets [1] Cost Management - Research and development expenses, along with selling and administrative expenses, are expected to narrow to between 29 billion and 30.9 billion yuan, reflecting prudent investment strategies that enhance revenue and pipeline growth [1]